With economics and politics in the way, can we defeat the malaria epidemic before it defeats us?

Patent pressures, changing disease profiles, and higher costs force companies to fight for the top.

The year 2011 may seem far off, but there is much to do to prepare for electronic pedigrees.

Letting the public inside the drug development process may increase their faith in what we do.

Getting IT, engineering, and manufacturing on the same page requires a delicate balance.

Was FDA's decision to issue a draft guidance on of-label information, amidst Congressional scrutiny, the right thing to do?

After two centuries, there's no reason to maintain two tablet compression tooling standards.

The author suggests a route for nanotechnology's future in the pharmaceutical industry.

With 2007 projects wrapped up, or so we hope, forward-looking companies need to take their next step.